Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 12, 2005, Pages 1459-1470

  Bonifazi, Floriano ^a,e   Jutel, M ^b   Bilo B M ^a   Birnbaum, J ^c   Muller, U ^d  

^a Allergy Unit   (Italy)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Hopital Ste Marguerite   (France)

^d Spital Bern Ziegler   (Switzerland)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

Immunotherapy; Pharmacological treatment; Prevention

Indexed keywords

ADRENALIN; ANT VENOM; ANTIHISTAMINIC AGENT; BEE VENOM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CETIRIZINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; GLUCAGON; HISTAMINE H1 RECEPTOR ANTAGONIST; HYMENOPTERA VENOM; IMMUNOGLOBULIN E ANTIBODY; INSECT VENOM; NORADRENALIN; PREDNISONE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VESPULA VENOM; WASP VENOM;

ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY SPECIFICITY; BRONCHUS OBSTRUCTION; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG OVERDOSE; DRUG SAFETY; ENVENOMATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INSECT ALLERGY; INSECT STING; LARYNX EDEMA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; REVIEW; SKIN TEST; SYMPTOMATOLOGY; TREATMENT OUTCOME; URTICARIA; URTICARIA PIGMENTOSA;

ADULT; ANAPHYLAXIS; ANIMALS; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; EPINEPHRINE; FEMALE; HUMANS; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; INSECT BITES AND STINGS; MALE; PRACTICE GUIDELINES; VENOMS;

EID: 27844541751     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00960.x     Document Type: Review

References (149)

1. Müller U, Mosbech H, Aberer W, Dreborg S, Ewan P, Kunkel G et al. EAACI position paper. Adrenaline for emergency kits. Allergy 1995;50:783-787.
2. Bousquet J, Müller UR, Dreborg S, Jarish R, Malling HJ, Mosbech H et al. Immunotherapy with Hymenoptera venoms. Allergy 1987;42:401-413.
3. Müller U, Mosbech H. Position paper. Immunotherapy with Hymenoptera venoms. EAACI. Allergy 1993;48:36-46.
4. Shekelle PG, Woolf SH, Eccles M, Grimsham J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-596.
5. Visscher PK, Vetter RS, Camazine S. Removing bee stings. Lancet 1996;348:301-302.
6. Toogood JH. Betablocker therapy and the risk of anaphylaxis. Can Med Assoc J 1987;136:929-933.
7. Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergy immunotherapy injections. J Allergy Clin Immunol 1990;85:407-411.
8. Müller UR. Insect sting allergy. Clinical picture, diagnosis and treatment. Stuttgart/New York: Gustav Fischer Verlag, 1990.
9. Portnoy JM, Moffitt JE, Golden DBK, Bernstein IL, Berger WE, Dykewicz MS et al. Stinging insect hypersensitivity: a practice parameter. J Allergy Clin Immunol 1999;103:963-980.
10. Müller U, Mosbech H, Blaauw P, Dreborg S, Malling HJ, Przybilla B et al. Emergency treatment of allergic reactions to Hymenoptera stings. Clin Exp Allergy 1991;21:281-288.
11. AAAAI Board of Directors. The use of epinephrine in the treatment of anaphylaxis. Position statement. J Allergy Clin Immunol 1994;94:666-668.
12. Project Team of the Resuscitation Council (UK). Emergency medical treatment of anaphylactic reactions. J Accid Emerg Med 1999;16:243-247.
13. Simons FER. First aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 2004;113:837-844.
14. Bautista E, Simons E, Simons K, Becker A, Duke K, Tillet M et al. Epinephrine fails to hasten hemodynamic recovery in fully developed canine anaphylactic shock. Int Arch Allergy Immunol 2002;128:151-164.
15. Gu X, Simons FER, Simons KJ. Epinephrine absorption after different routes of administration in an animal model. Biopharm Drug Dispos 1999;20:401-405.
16. Simons FER, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injections. J Allergy Clin Immunol 2001;108:871-873.
17. Cummins RO, Hazinski MR. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: An international consensus on science: American heart association in collaboration with the international liaison committee on resuscitation (ILCOR). Part 8: advanced challenges in resuscitation. Circulation 2000;102(Suppl.):I229-I252.
18. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gildman's. The pharmacological basis of therapeutics. 9th edn. New York: McGraw-Hill Companies Inc., 1996:204-209.
19. Pumphrey RSH. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000;30:1144-1150.
20. Grouhi M, Alshehri M, Hummel D, Roifman CM. Anaphylaxis and epinephrine auto-injector training: who will teach the teachers? J Allergy Clin Immunol 1999;104:190-193.
21. Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an epinephrine auto-injector device (Epipen). J Allergy Clin Immunol 2000;106:171-176.
22. Creticos PS, Franklin Adkinson N Jr, Kagey-Sabotka A, Proud D, Meier HL, Naclerio RM et al. Nasal challenge with ragweed in hay fever patients: effect of immunotherapy. J Clin Invest 1985;76:2247-2253.
23. 2 antibodies. Int Arch Allergy Appl Immunol 1985;77:195-197.
24. Rak S, Rowhagen O, Venge P. The effect of immunotherapy on bronchial hyper-responsiveness and eosinophil cationic protein in pollen allergic patients. J Allergy Clin Immunol 1988;82:470-480.
25. Jutel M, Müller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996;26:1112-1118.
26. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676-1683.
27. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of IL-10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
28. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914-925.
29. Akdis CA, Blaser K. IL-10 induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999;13:603-609.
30. 2 induces specific T cell anergy in bee sting allergic patients. J Allergy Clin Immunol 1998;101:747-754.
31. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures. J Immunol 1995;154:4178-4194.
32. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:1131-1139.
33. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sabotka A, Lichtenstein LM et al. Effects of peptide therapy on ex vivo T cell responses. J Allergy Clin Immunol 1998;101:506-513.
34. Akdis CA, Blesken T, Akdis M, Alkan SS, Heusser CH, Blaser K. Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro. Eur J Immunol 1997;27:2351-2357.
35. 2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and non-specific activation of T and B cells. J Allergy Clin Immunol 1997;99:345-352.
36. 2. J Immunol 1993;150:3582-3591.
37. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alfa-chains (CD25). Breakdown of a single mechanism of self tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
38. Groux H, O'garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
39. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423-449.
40. Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 2001;13:644.
41. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-1218.
42. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
43. low T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 1998;28:3435-3447.
44. + T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-1290.
45. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K et al. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:233-241.
46. Kammerer R, Chvatchko Y, Kettner A, Dufour N, Corradin G, Spertini F. Modulation of T-cell responses to phospholipase A2 and phospholipase A2-derived peptides by conventional Bee venom immunotherapy. J Allergy Clin Immunol 1997;100:96-103.
47. Stephan V, Kuhr J, Urbanek R. Relevance of basophil histamine release changes during venom immunotherapy. Allergy 1989;44:453-459.
48. Bernstein DI, Mittman RJ, Kagen SL, Korbee L, Enrione M, Bernstein IL. Clinical and immunologic studies of rapid immunotherapy in Hymenoptera sensitive patients. J Allergy Clin Immunol 1989;84:951-959.
49. Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitisation. Clin Exp Allergy 1995;25:704-712.
50. Berchtold E, Maibach R, Müller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pre-treatment with terfenadine. Clin Exp Allergy 1992;22:59-65.
51. Brockow K, Kiehn M, Riethuä C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized placebo-controlled trial. J Allergy Clin Immunol 1997;100:458-463.
52. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001;107:81-86.
53. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR, Malolepszy J et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420-425.
54. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-161.
55. Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979;34:369-378.
56. Brown S, Wiese M, Blackman K, Heddle R. Ant venom immunotherapy: A double blind, placebo-controlled cross-over trial. Lancet 2003;361:1001-1006.
57. Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG, EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005;60:1339-1349.
58. Tunon-De-Lara JM, Villanueva P, Marcos M, Taytard A. Ace inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992;340:908.
59. Ober AI, Maclean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003;112:1008-1009.
60. Schuberth KC, Lichtenstein LM, Kagey-Sobotka AK, Szklo M, Kwiterovich KA, Valentine MD. Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. J Pediatr 1983;102:361-365.
61. Graft DF, Schuberth KC, Kagey-Sobotka AK, Kwiterovich KA, Niu Y, Lichtenstein LM et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr 1984;104:664-668.
62. Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984;74:494-498.
63. Schwartz HJ, Golden DBK, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990;85:709-712.
64. Kochuyt AM, Van Hoeyveld E, Stevens EAM. Occupational allergy to bumble bee venom. Clin Exp Allergy 1993;23:190-195.
65. Bucher C, Korner P, Wüthrich B. Allergy to bumblebee venom. Curr Opin Allergy Immunol 2001;1:361-365.
66. Stern A, Mullner RG, Wüthrich B. Successful treatment of occupational allergy to bumble-bee venom after failure with honeybee venom extract. Allergy 2000;55:88-91.
67. Reisman RE, Müller UR, Wypych JI, Lazell MI. Studies of coexisting honeybee and vespid-venom sensitivity. J Allergy Clin Immunol 1984;73:246-252.
68. Straumann F, Bucher C, Wüthrich B. Double sensitization to honeybee and wasp venom: immunotherapy with one venom or with both venoms? Int Arch Immunol 2000;123:268-274.
69. Lichtenstein LM, Valentine MD, Sobotka AK. A case for venom treatment in anaphylactic sensitivity to Hymenoptera sting. N Engl J Med 1974;290:1223-1227.
70. Golden DBK, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980;92:620-624.
71. Ramirez DA, Londono SA, Evans R. Adverse reactions to venom immunotherapy. Ann Allergy 1981;47:435.
72. Tarhini H, Knani J, Michel FB, Bousquet J. Safety of venom immunotherapy administered by cluster schedule. J Allergy Clin Immunol 1992;89:1198-1199.
73. Yunginger JW, Paull BR, Jones RT, Santrach PJ. Rush venom immunotherapy program for honeybee sting sensitivity. J Allergy Clin Immunol 1979;63:340-347.
74. Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol 1987;79:947-954.
75. Müller U, Morris T, Bischof M, Friedli H, Skarvil F. Combined active and passive immunotherapy in honeybee-sting allergy. J Allergy Clin Immunol 1986;78:115-122.
76. Gillman SA, Cummins LH, Kozak PP, Hoffman DR. Venom immunotherapy: comparison of «rush» vs «conventional» schedules. Ann Allergy 1980;45:351-354.
77. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980;92:620-624.
78. Laurent J, Smiejan JM, Bloch-Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997;52:94-96.
79. Michils A, Baldassarre S, Ledent C, Mairesse M, Gossart B, Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy 2000;55:455-462.
80. Van Der Zwan JC, Flinterman J, Jankowski IG, Kerckhaert JAM. Hyposensitization to wasp venom in six hours. BMJ 1983;287:1329-1331.
81. Bernstein AJ, Kagen SI, Bernstein DI. Rapid venom immunotherapy is safe routine in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994;73:423-442.
82. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23:226-230.
83. Van Der Brempt X, Ledent C, Mairesse M. Accelerated desensitization for Hymenoptera venom allergy in 30 hours: efficacy and safety in 150 cases. Rev Med Brux 1997;18:120-124.
84. Lockey RF, Turkeltaub PC, Olive ES, Hussard JM, Baird-Warren IA, Buckantz SC. The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-780.
85. Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000;55:1005-1010.
86. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-535.
87. Hoffman DR, Jacobson RS. Allergens in Hymenoptera venoms. XII. How much protein is in a sting? Ann Allergy 1984;52:276-278.
88. Sanchez F, Blanca M, Miranda A, Carmona M, Garcia J, Fernandez X et al. Comparison of Vespula Germanica venoms obtained from different sources. Int Arch Immunol 1994;104:385-389.
89. Wood C, Benson E, Timmons E, Hoffman D. Allergens in Hymenoptera venoms. X. Vespid venoms versus venom extracts: comparison by two-dimensional polyacrylamide gel electrophoresis. Ann Allergy 1983;51:441-445.
90. Youlten L, Atkinson B, Lee T. The incidence and the nature of adverse reaction to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy 1995;25:159-165.
91. Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000;105:1231-1235.
92. De Jong NW, Vermeulen AM, De Groot H. Allergy to bumblebee venom. III. Immunotherapy follow-up study (safety and efficacy) in patients with occupational bumblebee-venom anaphylaxis. Allergy 1999;54:980-984.
93. De Groot H, De Graaf-In't Veld C, Van Wijk RG. Allergy to bumblebee venom. I. Occupational anaphylaxis to bumblebee venom: diagnosis and treatment. Allergy 1995;50:581-584.
94. Reimers RE, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55:484-488.
95. Scribner TA, Bernstein DI. Rapid venom immunotherapy update. Curr Opin Allergy Clin Immunol 2003;3:295-298.
96. Przybilla B, Ring J, Galosi A, Geursen RG, Stickl HA. Bee venom immunoglobulin for prophylaxis of anaphylactic reactions during bee venom immunotherapy (rush hyposensitization). Immunol Allergy Pract 1986;8:107-111.
97. Jarisch R. Passive immunotherapy in bee venom allergic patients. Arch Dermatol Res 1981;270:230-235.
98. Malling HJ, Djurup R, Sondergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom. Allergy 1985;40:373-383.
99. Müller U, Rabson A, Bischof M, Lomnitzer R, Dreborg S, Lanner A. A double-blind study comparing monomethoxy polyethylene glycol modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. J Allergy Clin Immunol 1987;80:252-261.
100. Wyss M, Scheitlin T, Stadler BM, Wüthrich B. Immunotherapy with aluminium hydroxide absorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993;48:81-86.
101. Quercia O, Rafanelli S, Puccinelli P, Stefanini GF. The safety of cluster immunotherapy with aluminium hydroxide-absorbed honeybee venom extract. J Investig Allergol Clin Immunol 2001;11:27-33.
102. Poli F, Longo G, Parmiani S. The safety and efficacy of immunotherapy with aluminium hydroxide-absorbed venom extract of Vespula spp. An open, retrospective study. Allergol Immunopathol (Madr) 2001;29:191-196.
103. Müller UR. Recombinant Hymenoptera venom allergens. Allergy 2002;57:570-576.
104. Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honey bee venom allergy: a comparative study using aqueous and aluminium adsorbed preparations. Allergy 2004;59:589-595.
105. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003;33:58-64.
106. Flicker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997;100:11-15.
107. Ruëff F, Ludolph-Hauser D, Przybilla B. Erhöhte basale Serumtryptrase als Risikofaktor der Insektengiftallergie. Allergo J 2003;12(sonderheft 1):S32-S38.
108. Haeberli G, Bronnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003;33:1216-1220.
109. Oude Elberink JNG, De Monchy JGR, Kors JW, Van Doormaal JJ, Dubois AEJ. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997;99:153-154.
110. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-1032.
111. Golden DBK. Practical considerations in venom immunotherapy. Allergy Asthma Proc 1997;18:79-80.
112. Golden D, Kagey-Sobotka A, Valentine M, Lichtenstein L. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370-374.
113. Bousquet J, Menardo JL, Michel FB. Systemic reactions during maintenance immunotherapy in honeybee venom. Ann Allergy 1988;61:63-68.
114. Golden DBK, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prolonged-maintenance interval in Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:482-484.
115. Gadde J, Sobotka A, Valentine M, Lichtenstein L, Golden D. Intervals of six and eight weeks in maintenance venom immunotherapy. Ann Allergy 1985;54:348.
116. Goldberg A, Reisman RE. Prolonged interval maintenance venom immunotherapy. Ann Allergy 1988;61:177-179.
117. Confino-Cohen R, Goldberg A, Mekori YA. Deliberate bee sting challenge of patients receiving maintenance venom immunotherapy at a 3-months interval. J Allergy Clin Immunol 1993;91:189-194.
118. Goldberg A, Confino-Cohen R, Mekori Y. Deliberate bee sting challenge of patients receiving maintenance venom immunotherapy at 3-months intervals. J Allergy Clin Immunol 1994;93:997-1001.
119. Kochuyt AM, Stevens EAM. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy. Clin Exp Allergy 1994;24:35-41.
120. Goldberg A, Confino-Cohen R. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol 2001;107:902-906.
121. Chipps B, Valentine M, Kagey-Sobotka A, Schuberth K, Lichtenstein L. Diagnosis and treatment of anaphylactic reactions to Hymenoptera stings in children. J Allergy Clin Immunol 1980;97:177-184.
122. Hoffman D, Gillman S, Cummins L, Kozak P, Oswald A. Correlation of IgG and IgE antibody levels to honey bee venom allergens with protection to sting challenge. Ann Allergy 1981;46:17-23.
123. Mosbech H, Malling H, Biering I, Böwadt H, Sooborg M, Weeke B, Löwenstein H. Immunotherapy with yellow jacket venom. Allergy 1984;39:543-549.
124. Urbanek R, Forster J, Kühn W, Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 1985;107:367-371.
125. Smith P, Kagey-Sobotka A, Bleeker E, Traystman R, Kaplan A, Gralnick H. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980;66:1072-1080.
126. Graft DF, Schubert KC, Kagey-Sobotka A, Kwiterovoch KA, Niv Y, Lichtenstein LM et al. Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987;80:162-169.
127. Valentine MD, Schubert KC, Kagey-Sobotka A, Graft DF, Kwiterovoch KA, Szklo M et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990;323:1601-1603.
128. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-612.
129. Blaauw PJ, Smithuis LOMJ. The evaluation of the common diagnostic methods of hypersensitivity for bee and yellow jacket venom by means of an in-hospital insect sting. J Allergy Clin Immunol 1985;75:556-562.
130. van der Linden PWG, Hack CE, Struyvenberg A, Van Der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994;94:151-159.
131. Rueff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Allergy 1996;51:216-225.
132. Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs, emotional distress and quality of life in patients given immunotherapy for insect sting allergy. Clin Exp Allergy 1999;29:1626-1631.
133. Oude Elberink J, De Monchy J, Van Der Heide S, Guyatt G, Dubois A. Venom immunotherapy improves health related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-182.
134. Golden DBK, Addison BI, Gadde J, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989;84:162-167.
135. Müller U, Berchtold E, Helbling A. Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991;87:702-709.
136. Haugaard L, Nörregaard OF, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991;87:699-702.
137. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991;88:339-348.
138. van Halteren HK, Van Der Linden PWG, Burgers JA, Bartelink AKM. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997;100:767-770.
139. Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993;92:831-836.
140. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996;97:579-587.
141. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: Extended observations. J Allergy Clin Immunol 1998;101:298-305.
142. Ludolph-Hauser D, Rueff F, Fries C, Schöpf P, Przybilla B. Constitutively raised serum concentration of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001;357:361-362.
143. Reisman RE, Lantner R. Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped by self-choice. J Allergy Clin Immunol 1989;83:1049-1054.
144. Müller U. Recent developments and future strategies for immunotherapy of insect venom allergy. Curr Opin Allergy Clin Immunol 2003;3:299-303.
145. Müller U, Soldatova L, Weber M. Bee venom allergy: comparison of IgE-binding capacity of purified natural and recombinant-synthetic venom allergens. J Allergy Clin Immunol 1998;101:33.
146. Valenta R, Lidholm J, Niederberger V, Hajek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component resolved diagnostics and immunotherapy. Clin Exp Allergy 1999;29:896-904.
147. Carballido J, Carballido M, Kägi M, Meloen T, Wüthrich B, Heusser C et al. T cell epitope specificity in human allergic and non allergic subjects to bee venom phospholipase A2. J Immunol 1993;150:3582-3591.
148. Jilek S, Barbey C, Spertini F, Corthesy B. Antigen independent suppression of the allergic immune response to bee venom phospholipase A2 by DNA vaccination in CBA/J mice. Immunology 2001;166:3612-3621.
149. Karamloo F, Kussebi F, Schmid-Grendelmeier P, Blaser K, Crameri R, Akdis C et al. Gene recombination of molecular bee venom allergen fragments as a novel vaccine for allergen specific immunotherapy. Proceedings of the second EAACI Davos meeting on basic allergy and clinical immunology. Davos 2003;60:16.